Table 3.
Demographic and clinical characteristics of CSBM responders within the first week of EA treatmenta.
| Characteristics | Non-responders | Responders | Total | P-valueb |
|---|---|---|---|---|
| (n=890) | (n=161) | (N=1051) | ||
| Age, mean (SD), y | 47.9 (15.91) | 42.5 (16.63) | 47.1 (16.13) | <0.001 |
| Race | 0.295 | |||
| Han | 863 (97.0) | 159 (98.8) | 1022 (97.2) | |
| Non-Han | 27 (3.0) | 2 (1.2) | 29 (2.8) | |
| BMI (kg/m2) | 0.419 | |||
| ≤18.5 | 53 (6.0) | 14 (8.7) | 67 (6.4) | |
| >18.5 to ≤23.9 | 573 (64.4) | 104 (64.6) | 677 (64.4) | |
| >23.9 to ≤27.9 | 229 (25.7) | 35 (21.7) | 264 (25.1) | |
| >27.9 | 35 (3.9) | 8 (5.0) | 43 (4.1) | |
| Constipation duration, y | 0.224 | |||
| ≤10 | 566 (63.6) | 118 (73.3) | 684 (65.1) | |
| >10 to ≤20 | 196 (22.0) | 27 (16.8) | 223 (21.2) | |
| >20 to ≤30 | 84 (9.4) | 12 (7.5) | 96 (9.1) | |
| >30 to ≤40 | 31 (3.5) | 3 (1.9) | 34 (3.2) | |
| >40 to ≤50 | 9 (1.0) | 0 (0.0) | 9 (0.9) | |
| >50 | 4 (0.4) | 1 (0.6) | 5 (0.5) | |
| CSBMs | <0.001 | |||
| ≤1 | 835 (93.8) | 106 (65.8) | 941 (89.5) | |
| >1 to ≤2 | 55 (6.2) | 55 (34.2) | 110 (10.5) | |
| PAC-QOL score | <0.001 | |||
| ≤2 | 127 (14.3) | 46 (28.6) | 173 (16.5) | |
| >2 to ≤3 | 468 (52.6) | 66 (41.0) | 534 (50.8) | |
| >3 to ≤4 | 259 (29.1) | 41 (25.5) | 300 (28.5) | |
| >4 to ≤5 | 36 (4.0) | 8 (5.0) | 44 (4.2) | |
| Comorbidity | 0.543 | |||
| Yes | 196 (22.0) | 32 (19.9) | 228 (21.7) | |
| No | 694 (78.0) | 129 (80.1) | 823 (78.3) |
BMI: body mass index; CSBM: complete spontaneous bowel movement; PAC-QOL: patient assessment of constipation quality of life.
aData are expressed as no. of participants (%) unless otherwise indicated; 24 participants missed the 1 wk defecation diaries but completed all other defecation diaries (9 in the EA group and 15 in the SA group).
bA threshold of P<0.25 was used to select variables [10].